Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04381650 · ClinicalTrials.gov registry record · Phase 1

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Takeda.

Completed
Registry status
Phase 1
Development phase
161
Enrollment target
20
Study locations

NCT04381650 is a Phase 1 study of Advanced or Metastatic Solid Tumors that has completed, run by Takeda. The registered enrollment target is 161 participants, below the 229-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04381650, a Phase 1 study of Advanced or Metastatic Solid Tumors, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 1
Development phase
161 participants
Enrollment target
20
Study locations

Study Summary

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors. The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab. Participants will be on this combination treatment for 21-day cycles. They will continue with this treatment for up to 24 months or until participants meet any discontinuation criteria.

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • DRUG Pembrolizumab
  • DRUG TAK-981

Study Locations (20)

California

  • University of California Irvine Medical Center - Orange
  • Stanford Cancer Institute (SCI) - Stanford

New Jersey

  • Morristown Medical Center - Morristown
  • Cancer Institute of New Jersey - New Brunswick

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia
  • UPMC Hillman Cancer Center - Pittsburgh

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • START South Texas Accelerated Research Therapeutics - San Antonio

Virginia

  • University of Virginia Health System - Charlottesville
  • Virginia Cancer Specialists (Fairfax) - USOR - Fairfax

Arizona

  • HonorHealth - Scottsdale

Connecticut

  • Yale Cancer Center - New Haven

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2020-08-17
Est. Completion 2024-10-29
Phase Phase 1

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04381650

The ClinicalTrials.gov registry entry for NCT04381650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (30% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT04381650 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New Jersey, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04381650 about?

NCT04381650 is a clinical study titled "A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors". TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors. The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab. Participants will be on this combinat...

What is the current status of trial NCT04381650?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 161 participants. The study started on 2020-08-17. Estimated completion is 2024-10-29.

What conditions does trial NCT04381650 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT04381650?

The interventions under investigation include: Pembrolizumab (DRUG), TAK-981 (DRUG).

Who is sponsoring clinical trial NCT04381650?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04381650 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.